C83.36 Diffuse large B-cell lymphoma, intrapelvic lymph nodes

Name of the Condition

• Diffuse Large B-Cell Lymphoma, Intrapelvic Lymph Nodes (ICD-10 Code: C83.36)

Summary

Diffuse large B-cell lymphoma (DLBCL) is an aggressive type of non-Hodgkin lymphoma that originates in B-cells, a type of white blood cell. It is characterized by rapidly growing tumors in the lymph nodes or other lymphoid tissues. This code specifies involvement of the intrapelvic lymph nodes. DLBCL is one of the most common subtypes of non-Hodgkin lymphoma and can occur in various parts of the body.

Causes

The exact cause of DLBCL is not fully understood. It is believed to result from genetic mutations in B-cells, which may be triggered by factors such as previous infections (e.g., Epstein-Barr virus), immune system dysfunctions, or exposure to certain environmental agents. These mutations disrupt normal cell growth and division, leading to uncontrolled proliferation.

Risk Factors

• Advanced age (most common in older adults)
• Weakened immune system (e.g., from HIV, organ transplants, or immunosuppressive drugs)
• Family history of lymphoma
• Exposure to certain chemicals or radiation
• Chronic infections (e.g., hepatitis C)

Symptoms

• Swollen, painless lymph nodes in the pelvic region
• Unexplained weight loss
• Fever
• Night sweats
• Fatigue
• Loss of appetite
• Abdominal or pelvic pain
• Urinary or bowel changes (if lymph nodes press on nearby structures)

Diagnosis

Diagnosis involves a combination of physical examination, imaging studies (e.g., CT or MRI scans) to identify lymph node involvement, and biopsy of the affected tissue. Pathologists examine the biopsy sample to confirm the presence of large B-cells and rule out other conditions. Additional tests, such as blood work or bone marrow biopsy, may be performed to stage the disease and assess overall health.

Treatment Options

Treatment typically includes chemotherapy, often with immunotherapy (e.g., rituximab). Radiation therapy may be used for localized disease. In some cases, stem cell transplantation or targeted therapies are considered, especially for relapsed or refractory disease. Treatment plans are tailored to the patient’s age, overall health, and disease stage.

Prognosis and Follow-Up

Prognosis varies based on factors like age, disease stage, and response to treatment. Many patients achieve remission with standard therapy, but some may experience recurrence. Regular follow-up appointments, including imaging and blood tests, are essential to monitor for relapse or complications. Long-term surveillance is recommended to detect late effects of treatment.

Complications

• Disease progression or recurrence
• Infection due to weakened immune system
• Organ damage from tumor growth or treatment
• Secondary cancers (rare, associated with certain therapies)
• Fatigue or other long-term side effects from treatment

Lifestyle & Prevention

• Maintain a balanced diet and regular exercise to support overall health.
• Avoid known carcinogens (e.g., tobacco, excessive alcohol).
• Practice good hygiene to reduce infection risk, especially if immunosuppressed.
• Stay up-to-date with vaccinations (as recommended by a healthcare provider).

When to Seek Professional Help

Seek medical attention if you experience persistent swollen lymph nodes, unexplained weight loss, fever, night sweats, or pelvic pain. Early evaluation is important for timely diagnosis and treatment.

Tips for Medical Coders

Use code C83.36 for diffuse large B-cell lymphoma specifically involving the intrapelvic lymph nodes. Ensure documentation supports the anatomical site (intrapelvic) to justify code assignment. Verify that the diagnosis aligns with histopathological confirmation of DLBCL and exclude other lymphoma subtypes or sites.